In a recent transaction, COWEN AND COMPANY, LLC (Trades, Portfolio), a prominent investment firm, acquired a substantial stake in Slam Corp (SLAMU, Financial). This article aims to provide an in-depth analysis of this transaction, the guru's profile, and the traded company's basic information. The data used in this article is accurate as of July 12, 2023.
Guru Profile: COWEN AND COMPANY, LLC (Trades, Portfolio)
Based in New York, COWEN AND COMPANY, LLC (Trades, Portfolio) is a renowned investment firm with a diverse portfolio. The firm's investment philosophy is centered around identifying high-growth opportunities in the market. As of the latest data, the firm holds 556 stocks, with a total equity of $851 million. The firm's top holdings include Avadel Pharmaceuticals PLC (AVDL, Financial), Establishment Labs Holdings Inc (ESTA, Financial), Stoke Therapeutics Inc (STOK, Financial), Avidity Biosciences Inc (RNA, Financial), and Sylvamo Corp (SLVM, Financial). The healthcare and financial services sectors dominate the firm's portfolio.
Transaction Details
On July 10, 2023, COWEN AND COMPANY, LLC (Trades, Portfolio) purchased 800,000 shares of Slam Corp at a price of $10.67 per share. This transaction resulted in a 10,000% change in the firm's holdings and had a 0.99% impact on the guru's portfolio. Following this transaction, the firm holds a 0.99% position in Slam Corp and a 3.16% stake in the total shares of the traded stock.
Traded Company Profile: Slam Corp
Slam Corp, symbol SLAMU, is a US-based blank check company. The company went public on February 23, 2021, and as of the latest data, its stock is priced at $10.6769. However, due to the nature of its business, the company's market capitalization and segments are not applicable.
Stock Performance and Valuation
Since its IPO, Slam Corp's stock has seen a 3.86% increase in price, with a year-to-date increase of 5.71%. However, due to the lack of sufficient data, the GF Valuation and the Price to GF Value cannot be evaluated. The stock's PE percentage stands at 9999.00%. The GF Score, a measure of the stock's future performance potential, is currently at 20, indicating poor future performance potential.
Stock Financial Health and Growth
Slam Corp's financial health and growth metrics are not particularly impressive. The company's rank balance sheet stands at 5, while its rank profitability is at 2. The company's F Score is 2, and its Z Score is 0.00, indicating potential financial distress. The company's ROE and ROA are 2.81% and 2.66% respectively, ranking 183 and 153 in these categories.
Stock Momentum and Predictability
Slam Corp's stock momentum and predictability metrics are also not very promising. The stock's RSI 5 Day, RSI 9 Day, and RSI 14 Day are 35.90, 50.45, and 53.81 respectively. The momentum index 6 - 1 month and 12 - 1 month are 2.17 and 5.38 respectively. However, due to insufficient data, the stock's rank predictability is not applicable.
Conclusion
In conclusion, COWEN AND COMPANY, LLC (Trades, Portfolio)'s recent acquisition of Slam Corp shares represents a significant addition to its portfolio. However, given Slam Corp's poor financial health and growth metrics, as well as its low GF Score, the stock's future performance potential appears to be limited. Value investors should carefully consider these factors before making investment decisions.
